Búsqueda | Portal de Búsqueda de la BVS España

1.

Impact of EBUS-TBNA in addition to [¹⁸F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC.

Guberina, Maja; Darwiche, Kaid; Hautzel, Hubertus; Ploenes, Till; Pöttgen, Christoph; Guberina, Nika; Herrmann, Ken; Umutlu, Lale; Wetter, Axel; Theegarten, Dirk; Aigner, Clemens; Eberhardt, Wilfried Ernst Erich; Schuler, Martin; Karpf-Wissel, Rüdiger; Stuschke, Martin.

Eur J Nucl Med Mol Imaging; 48(9): 2894-2903, 2021 08.

Artículo en Inglés | MEDLINE | ID: mdl-33547554

2.

[Criteria for inpatient diagnostic and treatment of patients with lung cancer, mesothelioma or thymoma]. / Kriterien für die Behandlung von thoraxonkologischen Erkrankungen als stationäre Leistung bei Erwachsenen.

Frost, Nikolaj; Wesseler, Claas; Wörmann, Bernhard; Eberhardt, Wilfried Ernst Erich.

Pneumologie; 78(4): 233-235, 2024 Apr.

Artículo en Alemán | MEDLINE | ID: mdl-38608657

3.

[Criteria for inpatient diagnostic and treatment of patients with lung cancer, mesothelioma or thymoma]. / Erratum: Kriterien für die Behandlung von thoraxonkologischen Erkrankungen als stationäre Leistung bei Erwachsenen.

Frost, Nikolaj; Wesseler, Claas; Wörmann, Bernhard; Eberhardt, Wilfried Ernst Erich.

Pneumologie; 78(4): e1, 2024 Apr.

Artículo en Alemán | MEDLINE | ID: mdl-38608660

4.

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Butts, Charles; Socinski, Mark A; Mitchell, Paul L; Thatcher, Nick; Havel, Libor; Krzakowski, Maciej; Nawrocki, Sergiusz; Ciuleanu, Tudor-Eliade; Bosquée, Lionel; Trigo, José Manuel; Spira, Alexander; Tremblay, Lise; Nyman, Jan; Ramlau, Rodryg; Wickart-Johansson, Gun; Ellis, Peter; Gladkov, Oleg; Pereira, José Rodrigues; Eberhardt, Wilfried Ernst Erich; Helwig, Christoph; Schröder, Andreas; Shepherd, Frances A.

Lancet Oncol; 15(1): 59-68, 2014 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-24331154

5.

A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer.

Metzenmacher, Martin; Kopp, Hans-Georg; Griesinger, Frank; Reinmuth, Niels; Sebastian, Martin; Serke, Monika; Waller, Cornelius Florian; Thomas, Michael; Eggert, Jochen; Schmid-Bindert, Gerald; Hoiczyk, Mathias; Christoph, Daniel Christian; Kimmich, Martin; Deuß, Burkhard; Seifert, Stephanie; Held, Swantje; Schuler, Martin; Herold, Thomas; Breitenbuecher, Frank; Eberhardt, Wilfried Ernst Erich.

Ther Adv Med Oncol; 13: 1758835921996506, 2021.

Artículo en Inglés | MEDLINE | ID: mdl-34104223

6.

Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.

Walter, Robert Fred Henry; Sydow, Saskia Roxanne; Berg, Erika; Kollmeier, Jens; Christoph, Daniel Christian; Christoph, Sandra; Eberhardt, Wilfried Ernst Erich; Mairinger, Thomas; Wohlschlaeger, Jeremias; Schmid, Kurt Werner; Mairinger, Fabian Dominik.

Cancer Manag Res; 11: 8711-8720, 2019.

Artículo en Inglés | MEDLINE | ID: mdl-31576173

7.

Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients.

Köhler, Jens; Schuler, Martin; Gauler, Thomas Christoph; Nöpel-Dünnebacke, Stefanie; Ahrens, Maike; Hoffmann, Andreas-Claudius; Kasper, Stefan; Nensa, Felix; Gomez, Benedikt; Hahnemann, Maria; Breitenbuecher, Frank; Cheufou, Danjouma; Özkan, Filiz; Darwiche, Kaid; Hoiczyk, Mathias; Reis, Henning; Welter, Stefan; Eberhardt, Wilfried Ernst Erich; Eisenacher, Martin; Teschler, Helmut; Stamatis, Georgios; Schmiegel, Wolff; Hahn, Stephan Albrecht; Baraniskin, Alexander.

J Cancer Res Clin Oncol; 142(4): 795-805, 2016 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-26687686

8.

Accelerated radiotherapy and concurrent chemotherapy for patients with contralateral central or mediastinal lung cancer relapse after pneumonectomy.

Pöttgen, Christoph; Abu Jawad, Jehad; Gkika, Eleni; Freitag, Lutz; Lübcke, Wolfgang; Welter, Stefan; Gauler, Thomas; Schuler, Martin; Eberhardt, Wilfried Ernst Erich; Stamatis, Georgios; Stuschke, Martin.

J Thorac Dis; 7(3): 264-72, 2015 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-25922702

9.

EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study.

Schuette, Wolfgang; Schirmacher, Peter; Eberhardt, Wilfried Ernst Erich; Fischer, Juergen R; von der Schulenburg, J-Matthias Graf; Mezger, Joerg; Schumann, Christian; Serke, Monika; Zaun, Silke; Dietel, Manfred; Thomas, Michael.

Cancer Epidemiol Biomarkers Prev; 24(8): 1254-61, 2015 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-26070531

10.

Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).

Eberhardt, Wilfried Ernst Erich; Pöttgen, Christoph; Gauler, Thomas Christoph; Friedel, Godehard; Veit, Stefanie; Heinrich, Vanessa; Welter, Stefan; Budach, Wilfried; Spengler, Werner; Kimmich, Martin; Fischer, Berthold; Schmidberger, Heinz; De Ruysscher, Dirk; Belka, Claus; Cordes, Sebastian; Hepp, Rodrigo; Lütke-Brintrup, Diana; Lehmann, Nils; Schuler, Martin; Jöckel, Karl-Heinz; Stamatis, Georgios; Stuschke, Martin.

J Clin Oncol; 33(35): 4194-201, 2015 Dec 10.

Artículo en Inglés | MEDLINE | ID: mdl-26527789

11.

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.

Zimmer, Lisa; Barlesi, Fabrice; Martinez-Garcia, Maria; Dieras, Veronique; Schellens, Jan H M; Spano, Jean-Philippe; Middleton, Mark R; Calvo, Emiliano; Paz-Ares, Luiz; Larkin, James; Pacey, Simon; Venturi, Miro; Kraeber-Bodéré, Françoise; Tessier, Jean J L; Eberhardt, Wilfried Ernst Erich; Paques, Michel; Guarin, Ernesto; Meresse, Valerie; Soria, Jean-Charles.

Clin Cancer Res; 20(16): 4251-61, 2014 Aug 15.

Artículo en Inglés | MEDLINE | ID: mdl-24947927

12.

Phase-I study of sagopilone in combination with cisplatin in chemotherapy-naive patients with metastasised small-cell lung cancer.

Gauler, Thomas Christoph; Christoph, Daniel Christian; Fischer, Juergen; Frickhofen, Norbert; Huber, Rudolf; Gonschorek, Christine; Roth, Katrin; Giurescu, Marius; Eberhardt, Wilfried Ernst Erich.

Eur J Cancer; 49(11): 2461-8, 2013 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-23692812

13.

Strategies for improving outcomes in NSCLC: a look to the future.

Stahel, Rolf; Peters, Solange; Baas, Paul; Brambilla, Elisabeth; Cappuzzo, Federico; De Ruysscher, Dirk; Eberhardt, Wilfried Ernst Erich; Felip, Enriqueta; Fennell, Dean; Marchetti, Antonio; Paz-Ares, Luis; Adjei, Alex A.

Lung Cancer; 82(3): 375-82, 2013 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-24094287

14.

10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL).

Eberhardt, Wilfried Ernst Erich; Gauler, Thomas Christoph; Lepechoux, Cecile; Stamatis, Georgios; Bildat, Stephan; Krbek, Thomas; Welter, Stefan; Grunenwald, Dominique; Fischer, Berthold; Rodrigo, Hepp de Los Rios; Theegarten, Dirk; Le Chevalier, Thierry; Seeber, Siegfried; Stuschke, Martin; Poettgen, Christoph.

Lung Cancer; 82(1): 83-9, 2013 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-23957964

15.

How Should We Choose the Best Therapy for Elderly Patients With Stage III Non-Small-Cell Lung Cancer?

Eberhardt, Wilfried Ernst Erich.

J Clin Oncol; 35(25): 2860-2862, 2017 09 01.

Artículo en Inglés | MEDLINE | ID: mdl-28537813

16.

Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.

Leijen, Suzanne; Middleton, Mark R; Tresca, Patricia; Kraeber-Bodéré, Françoise; Dieras, Veronique; Scheulen, Max E; Gupta, Avinash; Lopez-Valverde, Vanesa; Xu, Zhi-Xin; Rueger, Ruediger; Tessier, Jean J L; Shochat, Eliezer; Blotner, Steve; Naegelen, Valerie Meresse; Schellens, Jan H M; Eberhardt, Wilfried Ernst Erich.

Clin Cancer Res; 18(17): 4794-805, 2012 Sep 01.

Artículo en Inglés | MEDLINE | ID: mdl-22767668

17.

Reply to the Letter to the Editor by Hendriks et al.

Eberhardt, Wilfried Ernst Erich; Mitchell, Alan; Rami-Porta, Ramon.

J Thorac Oncol; 11(3): e43-4, 2016 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-26922925

18.

Concurrent chemoradiotherapy in stage III non-small-cell lung cancer: what is the best regimen?

Eberhardt, Wilfried Ernst Erich.

J Clin Oncol; 33(6): 532-3, 2015 Feb 20.

Artículo en Inglés | MEDLINE | ID: mdl-25559800

19.

Reply to D.A. Palma et al and A. Addeo et al.

Eberhardt, Wilfried Ernst Erich.

J Clin Oncol; 33(26): 2929-30, 2015 Sep 10.

Artículo en Inglés | MEDLINE | ID: mdl-26215943

20.

Staging of the mediastinum: are we already there?

Eberhardt, Wilfried Ernst Erich; Hepp, Rodrigo.

J Thorac Oncol; 8(9): 1114-5, 2013 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-23945380

Portal de Búsqueda de la BVS España

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Impact of EBUS-TBNA in addition to [¹⁸F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC.

[Criteria for inpatient diagnostic and treatment of patients with lung cancer, mesothelioma or thymoma]. / Kriterien für die Behandlung von thoraxonkologischen Erkrankungen als stationäre Leistung bei Erwachsenen.

[Criteria for inpatient diagnostic and treatment of patients with lung cancer, mesothelioma or thymoma]. / Erratum: Kriterien für die Behandlung von thoraxonkologischen Erkrankungen als stationäre Leistung bei Erwachsenen.

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer.

Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.

Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients.

Accelerated radiotherapy and concurrent chemotherapy for patients with contralateral central or mediastinal lung cancer relapse after pneumonectomy.

EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study.

Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.

Phase-I study of sagopilone in combination with cisplatin in chemotherapy-naive patients with metastasised small-cell lung cancer.

Strategies for improving outcomes in NSCLC: a look to the future.

10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL).

How Should We Choose the Best Therapy for Elderly Patients With Stage III Non-Small-Cell Lung Cancer?

Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.

Reply to the Letter to the Editor by Hendriks et al.

Concurrent chemoradiotherapy in stage III non-small-cell lung cancer: what is the best regimen?

Reply to D.A. Palma et al and A. Addeo et al.

Staging of the mediastinum: are we already there?